Stimulation of dendritic cells by DAMPs in ALA-PDT treated SCC tumor cells

Oncotarget

Volumn 6, Issue 42, 2015, Pages 44688-44702

  Wang, Xiaojie ^a   Ji, Jie ^a   Zhang, Haiyan ^a   Fan, Zhixia ^a   Zhang, Linglin ^a   Shi, Lei ^a   Zhou, Feifan ^b   Chen, Wei R ^a,b   Wang, Hongwei ^c   Wang, Xiuli ^a  

^a Shanghai Skin Disease Hospital   (China)

^b UNIVERSITY OF CENTRAL OKLAHOMA   (United States)

^c FUDAN UNIVERSITY   (China)

Author keywords

5 aminolevulinic acid mediated photodynamic therapy; Danger associated molecular patterns; Dendritic cells; Immune responses; Squamous cell carcinoma

Indexed keywords

AMINOLEVULINIC ACID; CALRETICULIN; HEAT SHOCK PROTEIN 70; HIGH MOBILITY GROUP B1 PROTEIN; CANCER VACCINE; CYTOKINE; HMGB1 PROTEIN, MOUSE; IMMUNOGLOBULIN RECEPTOR; PHOTOSENSITIZING AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER IMMUNIZATION; CELL MATURATION; CONTROLLED STUDY; DENDRITIC CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE ACTIVATED CELL SORTING; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PHOTODYNAMIC THERAPY; PROTEIN EXPRESSION; SKIN CARCINOMA; WESTERN BLOTTING; ANIMAL; CANCER TRANSPLANTATION; CARCINOMA, SQUAMOUS CELL; FEMALE; IMMUNOLOGY; METABOLISM; PATHOLOGY; PHENOTYPE; PHOTOCHEMOTHERAPY; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; TIME FACTOR;

AMINOLEVULINIC ACID; ANIMALS; CALRETICULIN; CANCER VACCINES; CARCINOMA, SQUAMOUS CELL; CYTOKINES; DENDRITIC CELLS; FEMALE; HMGB1 PROTEIN; HSP70 HEAT-SHOCK PROTEINS; MICE; NEOPLASM TRANSPLANTATION; PHENOTYPE; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; RECEPTORS, IMMUNOLOGIC; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; TIME FACTORS;

EID: 84953449871     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.5975     Document Type: Article

References (48)

1. Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. Annu Rev Immunol. 2013; 31:51-72.
2. Garg AD, Dudek AM, Agostinis P. Cancer immunogenicity, danger signals, and DAMPs: what, when, and how?. Bio Factors. 2013; 4:355-67.
3. Krysko DV, Garg AD, Kaczmarek A, Krysko O, Agostinis P, Vandenabeele P. Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer. 2012; 12:860-875.
4. Calvet CY, Famin D, Andre FM, Mir LM. Electrochemotherapy with bleomycin induces hallmarks of immunogenic cell death in murine colon cancer cells. Oncoimmunology. 2014; 3:e28131-e281310.
5. Garg AD, Krysko DV, Vandenabeele P, Agostinis P. DAMPs and PDT-mediated photo-oxidative stress: exploring the unknown. Photochem Photobiol Sci. 2011; 10:670-680.
6. Garg AD, Nowis D, Golab J, Vandenabeele P, Krysko DV, Agostinis P. Immunogenic cell death, DAMPs and anticancer therapeutics: an emerging amalgamation. Biochim Biophys Acta. 2010; 1805:53-71.
7. Michalak M, Groenendyk J, Szabo E, Gold LI, Opas M. Calreticulin, a multi-process calcium-buffering chaperone of the endoplasmic reticulum. Biochem J. 2009; 417:651-666.
8. Casares N1, Pequignot MO, Tesniere A, Ghiringhelli F, Roux S, Chaput N, Schmitt E, Hamai A, Hervas-Stubbs S, Obeid M, Coutant F, Métivier D, Pichard E, et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med. 2005; 202:1691-1701.
9. Rovere-Querini P, Castiglioni A. Adjuvant role for cell death during chemo- and radiotherapy of cancer?. Expert Rev Clin Immunol. 2008; 4:27-32.
10. Jiang Y, Dey S, Matsunami H. Calreticulin: roles in cell-surface protein expression. Membranes. 2014; 4:630-641.
11. Martins I, Kepp O, Galluzzi L, Senovilla L, Schlemmer F, Adjemian S, Menger L, Michaud M, Zitvogel L, Kroemer G. Surface-exposed calreticulin in the interaction between dying cells and phagocytes. Ann N Y Acad Sci. 2010; 1209:77-82.
12. Garg AD, Krysko DV, Vandenabeele P, Agostinis P. Hypericin-based photodynamic therapy induces surface exposure of damage-associated molecular patterns like HSP70 and calreticulin. Cancer Immunol Immunother. 2012; 61:215-221.
13. Gardai SJ1, McPhillips KA, Frasch SC, Janssen WJ, Starefeldt A, Murphy-Ullrich JE, Bratton DL, Oldenborg PA, Michalak M, Henson PM. Cell-surface calreticulin initiates clearance of viable or apoptotic cells through trans-activation of LRP on the phagocyte. Cell. 2005; 123:321-334.
14. Ghiringhelli F, Apetoh L, Tesniere A, Aymeric L, Ma Y, Ortiz C, Vermaelen K, Panaretakis T, Mignot G, Ullrich E, Perfettini JL, Schlemmer F, Tasdemir E, Uhl M, et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med. 2009; 15:1170-1178.
15. Yu Z, Geng J, Zhang M, Zhou Y, Fan Q, Chen J. Treatment of osteosarcoma with microwave thermal ablation to induce immunogenic cell death. Oncotarget. 2014; 5:6526-6539.
16. Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL, Castedo M, Mignot G, Panaretakis T, Casares N, Métivier D, Larochette N, van Endert P, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med. 2007; 13:54-61.
17. Lanneau D, Brunet M, Frisan E, Solary E, Fontenay M, Garrido C. Heat shock proteins: essential proteins for apoptosis regulation. J Cell Mol Med. 2008; 12:743-761.
18. Korbelik M, Sun J, Cecic I. Photodynamic therapy-induced cell surface expression and release of heat shock proteins: relevance for tumor response. Cancer Res. 2005; 65:1018-1026.
19. Schmitt E, Gehrmann M, Brunet M, Multhoff G, Garrido C. Intracellular and extracellular functions of heat shock proteins:repercussions in cancer therapy. J Leukoc Biol. 2007; 81:15-27.
20. Muller S, Ronfani L, Bianchi ME. Regulated expression and subcellular localization of HMGB1, a chromatin protein with a cytokine function. J Intern Med. 2004; 255:332-343.
21. Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature. 2002; 418:191-195.
22. Buytaert E, Dewaele M, Agostinis P. Molecular effectors of multiple cell death pathways initiated by photodynamic therapy. Biochim Biophys Acta. 2007; 1776:86-107.
23. Panzarini E, Inguscio V, Dini L. Immunogenic cell death: can it be exploited in PhotoDynamic Therapy for cancer? Biomed Res Intl. 2013; 2013:482160.
24. Garg AD, Krysko DV, Verfaillie T, Kaczmarek A, Ferreira GB, Marysael T, Rubio N, Firczuk M, Mathieu C, Roebroek AJ, et al. A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death. EMBO J. 2012; 31:1062-1079.
25. Zheng Y, Yin G, Le V, Zhang A, Lu Y, Yang M, Fei Z, Liu J. Hypericin-based Photodynamic Therapy Induces a Tumor-Specific Immune Response and an Effective DC-based cancer Immunotherapy. Biochemical Pharmacology. 2014; Feb 6.
26. Ji J, Fan Z, Zhou F, Wang X, Shi L, Zhang H, Wang P, Yang D, Zhang L, Chen WR, Wang X. Improvement of DC vaccine with ALA-PDT induced immunogenic apoptotic cells for skin squamous cell carcinoma. Oncotarget. 2015; 6:17135-17146.
27. Jingjing Li, Ting Lv, Hongwei Wang, Peiru Wang, Xiuli Wang. The mechanism of 5-aminolevulinic acid mediated photodynamic therapy treating cutaneous Squamous cell carcinoma in mouse model. Chin J Dermatol. 2014; 47:181-185. Chinese.
28. Robsahm TE, Helsing P, Veierod MB. Cutaneous squamous cell carcinoma in norway 1963-2011: increasing incidence and stable mortality. Cancer Med. 2015; 4:472-480.
29. Wang X, Shi L, Tu Q, Wang H, Zhang H, Wang P, Zhang L, Huang Z, Zhao F, Luan H, Wang X. Treating cutaneous squamous cell carcinoma using 5-aminolevulinic acid polylactic-co-glycolic acid nanoparticle-mediated photodynamic therapy in a mouse model. Int J Nanomedicine. 2015; 10:347-355.
30. Evangelou G, Farrar MD, Cotterell L, Andrew S, Tosca AD, Watson RE, Rhodes LE. Topical photodynamic therapy significantly reduces epidermal Langerhans cells during clinical treatment of basal cell carcinoma. Br J Dermatol. 2012; 166:1112-1115.
31. Wang HW, Lv T, Zhang LL, Lai YX, Tang L, Tang YC, Huang Z, Wang XL. A prospective pilot study to evaluate combined topical photodynamic therapy and surgery for extramammary paget's disease. Lasers Surg Med. 2013; 45:296-301.
32. Ko DY, Kim KH, Song KH. A randomized trial comparing methyl aminolaevulinate photodynamic therapy with and without Er:YAG ablative fractional laser treatment in Asian patients with lower extremity Bowen disease: results from a 12-month follow-up. Br J Dermatol. 2014; 170:165-172.
33. Kepp O, Senovilla L, Vitale I, Vacchelli E, Adjemian S, Agostinis P, Apetoh L, Aranda F, Barnaba V, Bloy N, Bracci L, Breckpot K, Brough D, et al. Consensus guidelines for the detection of immunogenic cell death. Oncoimmunology. 2014; 3:e955691.
34. Korbelik M, Banath J, Saw KM, Zhang W, Ciplys E. Calreticulin as cancer treatment adjuvant: combination with photodynamic therapy and photodynamic therapy-generated vaccines. Front Oncol. 2015; 5:15.
35. Garg AD, Nowis D, Golab J, Agostinis P. Photodynamic therapy: illuminating the road from cell death towards anti-tumour immunity. Apoptosis. 2010; 15:1050-1071.
36. Park JS1, Svetkauskaite D, He Q, Kim JY, Strassheim D, Ishizaka A, Abraham E. Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J Biol Chem. 2004; 279:7370-7377.
37. Yang D, Chen Q, Yang H, Tracey KJ, Bustin M, Oppenheim JJ. High mobility group box-1 protein induces the migration and activation of human dendritic cells and acts as an alarmin. J Leukoc Biol. 2007; 81:59-66.
38. Orlova VV, Choi EY, Xie C, Chavakis E, Bierhaus A, Ihanus E, Ballantyne CM, Gahmberg CG, Bianchi ME, Nawroth PP, et al. A novel pathway of HMGB1-mediated inflammatory cell recruitment that requires Mac-1-integrin. EMBO J. 2007; 81:59-66.
39. Green DR, Ferguson T, Zitvogel L, Kroemer G. Immunogenic and tolerogenic cell death. Nat Rev Immunol. 2009; 9:353-363.
40. Chow MT, Möller A, Smyth MJ. Inflammation and immune surveillance in cancer. Semin Cancer Biol. 2012; 22:23-32.
41. Vopenkova K, Mollova K, Buresova I, Michalek J. Complex evaluation of human monocyte-derived dendritic cells for cancer immunotherapy. J Cell Mol Med. 2012; 16:2827-2837.
42. Jung NC, Kim HJ, Kang MS, Lee JH, Song JY, Seo HG, Bae YS, Lim DS. Photodynamic therapy-mediated DC immunotherapy is highly effective for the inhibition of established solid tumors. Cancer Lett. 2012; 324:58-65.
43. Baltazar Lde M1, Santos PC, Paula TP, Rachid MA, Cisalpino PS, Souza DG, Santos DA. IFN-gamma impairs Trichophyton rubrum proliferation in a murine model of dermatophytosis through the production of IL-1beta and reactive oxygen species. Med Mycol. 2014; 52:293-302.
44. Ikeda H, Chamoto K, Tsuji T, Suzuki Y, Wakita D, Takeshima T, Nishimura T. The critical role of type-1 innate and acquired immunity in tumor immunotherapy. Cancer Sci. 2004; 95:697-703.
45. Kirkwood JM, Lee S, Moschos SJ, et al. Immunogenicity and antitumor effects of vaccination with peptide vaccine+/-granulocyte-monocyte colony-stimulating factor and/or IFN-alpha2b in advanced metastatic melanoma: Eastern Cooperative Oncology Group Phase II Trial E1696. Clin Cancer Res. 2009; 15:1443-1451.
46. Loison E, Gougeon ML. Thimerosal compromises human dendritic cell maturation, IL-12 production, chemokine release, and T-helper polarization. Hum Vaccin Immunother. 2014; 10:2328-2335.
47. Korbelik M. Complement upregulation in photodynamic therapy-treated tumors: Role of Toll-like receptor pathway and NFkappaB. Cancer Lett. 2009; 281:232-238.
48. Tanner M1, Kapanen AI, Junttila T, Raheem O, Grenman S, Elo J, Elenius K, Isola J. Characterization of a novel cell line established from a patient with Herceptin-resistant breast cancer. Mol Cancer Ther. 2004; 3:1585-1592.